Unknown

Dataset Information

0

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.


ABSTRACT: Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive B-cell lymphomas. Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options are available. Two CAR T-cell products [axicabtagene ciloleucel (axi-cel) and tisagenlecleucel] have obtained US Food and Drug Administration approval for the treatment of refractory DLBCL after two lines of therapy. A third product, liso-cel, is currently being evaluated in clinical trials and preliminary results appear very promising. CAR T-cell-related toxicity with cytokine-release syndrome and neurotoxicity remain important potential complications of this therapy. Here, we review the s biology, structure, clinical trial results and toxicity of two commercially approved CAR T-cell products and others currently being studied in multicenter clinical trials in B-cell NHLs.

SUBMITTER: Chavez JC 

PROVIDER: S-EPMC6466472 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.

Chavez Julio C JC   Bachmeier Christina C   Kharfan-Dabaja Mohamed A MA  

Therapeutic advances in hematology 20190415


Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive B-cell lymphomas. Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options are available. Two CAR T-cell products [axicabtagene ciloleucel (axi-cel) and ti  ...[more]

Similar Datasets

| S-EPMC6880960 | biostudies-literature
| S-EPMC9599140 | biostudies-literature
| S-EPMC7854294 | biostudies-literature
| S-EPMC9211527 | biostudies-literature
| S-EPMC8446909 | biostudies-literature
| S-EPMC7966809 | biostudies-literature
| S-EPMC8725814 | biostudies-literature
| S-EPMC4732525 | biostudies-other
2020-11-15 | GSE116975 | GEO